A Randomized, multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advances Hepatocellular Carcinoma

Project: Research

StatusActive
Effective start/end date4/10/193/10/24

Keywords

  • clinical trial
  • treatment efficacy
  • liver cancer
  • phase 3 study